
Maciej Wieczorek, MD, discusses CPL'36, a new PDA101 inhibitor with a novel mechanism of action for treatment of schizophrenia.

Maciej Wieczorek, MD, discusses CPL'36, a new PDA101 inhibitor with a novel mechanism of action for treatment of schizophrenia.